The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

“The journey through these phases varies for each person and may cycle, depending on the response to treatment and external stressors,” says Michael Kane, MD, a psychiatrist and the chief ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY ...

For patients with schizophrenia, repetitive transcranial magnetic stimulation (rTMS) was effective and safe in treating ...

US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptoms ...

New research highlights neuroglia (or glia cells) as critical players in mental health, potentially influencing conditions like depression and schizophrenia.

AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed ...